Minvasys: Tailoring the Stent to Fit the Lesion in Bifurcations
Executive Summary
Bifurcated lesions remain one of the most challenging unmet clinical needs facing interventional cardiologists, even with current drug-eluting stents. Here's how one small company is challenging bigger players in this promising market by developing polymer-free DES designed specifically for these difficult bifurcated lesions.
You may also be interested in...
Cappella: Can a New Twist On An Old Idea Solve the Bifurcation Challenge?
Device companies large and small have failed repeatedly in efforts to address bifurcations, which remain one of the largest unmet opportunities in cardiology. Cappella thinks it can solve the problem with a device that's a new version of an old idea, reversing current protocol to treat the side branch first.
Cappella: Can a New Twist On An Old Idea Solve the Bifurcation Challenge?
Device companies large and small have failed repeatedly in efforts to address bifurcations, which remain one of the largest unmet opportunities in cardiology. Cappella thinks it can solve the problem with a device that's a new version of an old idea, reversing current protocol to treat the side branch first.
Tryton Medical: Going Against the Flow in Bifurcated Stents
Many device companies, large and small, have tried unsuccessfully to come up with a stent to treat bifurcated lesions, primarily by focusing on treating the main vessel. Tryton is taking a different approach: using a bare-metal device designed to treat the side branch. The company believes this contrarian strategy pairs perfectly with current drug-eluting stents, making them an ideal acquisition target for a large CV company.